Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/18988
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTerpos, E.en
dc.contributor.authorMougiou, A.en
dc.contributor.authorKouraklis, A.en
dc.contributor.authorChatzivassili, A.en
dc.contributor.authorMichalis, E.en
dc.contributor.authorGiannakoulas, N.en
dc.contributor.authorManioudaki, E.en
dc.contributor.authorLazaridou, A.en
dc.contributor.authorBakaloudi, V.en
dc.contributor.authorProtopappa, M.en
dc.contributor.authorLiapi, D.en
dc.contributor.authorGrouzi, E.en
dc.contributor.authorParharidou, A.en
dc.contributor.authorSymeonidis, A.en
dc.contributor.authorKokkini, G.en
dc.contributor.authorLaoutaris, N. P.en
dc.contributor.authorVaipoulos, G.en
dc.contributor.authorAnagnostopoulos, N. I.en
dc.contributor.authorChristakis, J. I.en
dc.contributor.authorMeletis, J.en
dc.contributor.authorBourantas, K. L.en
dc.contributor.authorZoumbos, N. C.en
dc.contributor.authorYataganas, X.en
dc.contributor.authorViniou, N. A.en
dc.date.accessioned2015-11-24T18:56:08Z-
dc.date.available2015-11-24T18:56:08Z-
dc.identifier.issn0007-1048-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18988-
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAnemia, Refractory/drug therapyen
dc.subjectAnemia, Refractory, with Excess of Blasts/drug therapyen
dc.subjectAnemia, Sideroblastic/drug therapyen
dc.subjectErythropoietin/*therapeutic useen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectMyelodysplastic Syndromes/*drug therapyen
dc.subjectProspective Studiesen
dc.subjectTreatment Outcomeen
dc.titleProlonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patientsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/12100145-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1046/j.1365-2141.2002.03583.x/asset/j.1365-2141.2002.03583.x.pdf?v=1&t=h2bovhm4&s=51979d8006fc82b691e365af91a69cf80b1f323d-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2002-
heal.abstractTreatment with recombinant human erythropoietin (rHuEpo) improves anaemia in approximately 20% of patients with myelodysplastic syndromes (MDS). We investigated the potential advantage of a prolonged administration of rHuEpo to achieve higher erythroid response rates (RR) in 281 MDS patients: 118 with refractory anaemia (RA), 77 with refractory anaemia and ringed sideroblasts (RARS), 59 with refractory anaemia with excess of blasts and blast count < 10% (RAEB-I), and 27 with RAEB and blast count between 11-20% (RAEB-II). rHuEpo was given subcutaneously at a dose of 150 U/kg thrice weekly, for a minimum of 26 weeks. Response to treatment was evaluated after 12 and 26 weeks of therapy. The overall RR was 45.1%; the RR for RA, RARS, RAEB-I and RAEB-II were 48.3%, 58.4%, 33.8% and 13% respectively. A significant increase in RR was observed at week 26 in RA, RARS and RAEB-I patients, as the response probability increased with treatment duration. The RR was higher in the good cytogenetic prognostic group and serum Epo level of > 150 U/l at baseline predicted for non-response. The median duration of response was 68 weeks and the overall risk of leukaemic transformation was 21.7%. These results suggest that prolonged administration of rHuEpo produces high and long-lasting erythroid RR in MDS patients with low blast counts, particularly in those with pretreatment serum Epo levels of < 150 U/l and good cytogenetic prognosis.en
heal.journalNameBr J Haematolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Terpos-2002-Prolonged administra.pdf122.72 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons